EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis

Giulia Fornaro, Patrizio Armeni, Andrea Albera, Michele Barbara

Otology & Neurotology Open · 2022

DOI: 10.1097/ono.0000000000000018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otology & Neurotology Open, 2022. Verfasst von Giulia Fornaro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research on Health and Social Care Management, SDA Bocconi School of Management, Bocconi University, Milan, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hearing loss (HL) prevalence in Italy is expected to increase due to population aging. Hearing aids (HAs) are the main tool for HL rehabilitation; however, cost-utility analyses of HAs are limited. Our objective was to estimate the cost-utility of HAs use. Study Design: Cost-utility analysis.

Setting

Italian National Healthcare Service, societal perspective. Patients, Intervention(s), and Main Outcome Measure(s): A multistate Markov model was developed to model a cohort of 55-year-old individuals starting from normal hearing and moving across HL states to compare cost-utility and net monetary benefit of HA use accompanied by post-purchase service, HA use alone, and no treatment. Parameters were estimated using secondary data. Incremental cost-utility ratio (ICUR) and incremental net monetary benefit (INMB) were computed against a €16,625/quality-adjusted life year (QALY) willingness-to-pay (WTP) threshold. Deterministic and probabilistic sensitivity analysis (DSA, PSA) was implemented to assess how uncertainty affected results. Scenario analysis was performed on different assumptions on costs, dropout and compliance rates.

Results

The model suggests HAs use is a cost-effective strategy compared to no treatment (in the base case: incremental costs €429–€476, incremental QALY gain 0.18 and 0.19, ICUR €2‚404/QALY–€2‚450/QALY, INMB €2‚476–€2‚682 for male and female cohort, respectively). By assuming no dropout, INMBs increase up to €10,643–€10,728. DSA highlights that utility weights contribute the most to model uncertainty, PSA shows that the treatment has 97.8%–97.3% probability of being cost-effective at the WTP threshold considered.

Conclusions

We proposed an original model to assess the cost-utility of HAs use; the application to the Italian setting suggests the treatment is cost-effective, reinforcing the importance of early uptake.

Schlagwörter

Stichwörter der Autor:innen

Cost-utility analysisHearing aidsHearing lossNet monetary benefit analysis

Autor:innen und Institutionen

  • Centre for Research on Health and Social Care Management, SDA Bocconi School of Management, Bocconi University, Milan, Italy.
  • Department of Social and Political Science, Bocconi University, Milan, Italy.
  • Dipartimento di Scienze Chirurgiche, Università degli Studi di Torino, Turin, Italy.
  • Department of Otorhinolaryngology, "Mons. Dimiccoli" Hospital, Barletta, Italy.

Zitieren

APA

Fornaro, G., Armeni, P., Albera, A., & Barbara, M. (2022). The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis. Otology & Neurotology Open. https://doi.org/10.1097/ono.0000000000000018

Vancouver

Fornaro G, Armeni P, Albera A, Barbara M. The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis. Otology & Neurotology Open. 2022. doi:10.1097/ono.0000000000000018

BibTeX
@article{Fornaro2022,
  author = {Fornaro, Giulia and Armeni, Patrizio and Albera, Andrea and Barbara, Michele},
  title = {The Value of Hearing Aids for the Italian NHS: A Cost-utility Analysis},
  journal = {Otology & Neurotology Open},
  year = {2022},
  doi = {10.1097/ono.0000000000000018}
}
Kostenlos starten →